CD274 and neoplasm: Particularly, the emergence of immune checkpoint inhibitors (ICIs, such as CTLA-4 and PD-1/PDL-1 inhibitor) (2) and adoptive cell therapy (chimeric antigen receptor T cells, CAR-T) (3) represents a turning point for tumor treatment.